b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">28674996</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>08</Month>\n            <Day>17</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>12</Month>\n            <Day>02</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1699-3055</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>20</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title>\n                <ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>169-175</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-017-1706-2</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-approval research or monitoring is important to determine real-world safety of new products; however, evidence is scant for vemurafenib in Japanese patients. In Japan, a unique system is officially obligated to investigate post-approval safety. Here we report the first adverse drug reaction (ADR) data from vemurafenib-treated Japanese patients with metastatic melanoma. Data were collected in an early post-marketing phase vigilance (EPPV) study.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">ADRs were events for which a causal relationship with vemurafenib could not be ruled out or was unknown. ADR data were collected for patients treated with vemurafenib (960\xc2\xa0mg bid) between 26 February and 25 August 2015.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 95 patients, 46 patients had 118 ADRs (24 serious ADRs in 13 patients). The most common serious ADRs were hypersensitivity (n\xc2\xa0=\xc2\xa01; 3 events), arthralgia (n\xc2\xa0=\xc2\xa02; 2 events), pyrexia (n\xc2\xa0=\xc2\xa02; 2 events) and drug eruption (n\xc2\xa0=\xc2\xa02; 2 events). Seven patients had serious skin disorders or hypersensitivity, six of whom had prior anti-programmed cell death-1 (PD-1) antibodies 5-35\xc2\xa0days before starting vemurafenib. ADR reports of serious skin disorders appeared to be collected more rapidly than previously reported. Cutaneous squamous cell carcinoma developed in only one patient.</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EPPV in Japanese vemurafenib-treated patients identified no new safety signals. The most serious skin and hypersensitivity ADRs occurred in patients with prior anti-PD-1 exposure. Cutaneous squamous cell carcinoma appeared to be rare in Japanese patients. Further research is needed to clarify whether prior treatment with anti-PD-1 agents or racial differences affect the characteristic profile of cutaneous ADRs in Japanese patients.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Uhara</LastName>\n                    <ForeName>H</ForeName>\n                    <Initials>H</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5391-3397</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Dermatology, Shinshu University School of Medicine, Nagano, Japan. uharah@sapmed.ac.jp.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan. uharah@sapmed.ac.jp.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kiyohara</LastName>\n                    <ForeName>Y</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tsuda</LastName>\n                    <ForeName>A</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Takata</LastName>\n                    <ForeName>M</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yamazaki</LastName>\n                    <ForeName>N</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>07</Month>\n                <Day>03</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Italy</Country>\n            <MedlineTA>Clin Transl Oncol</MedlineTA>\n            <NlmUniqueID>101247119</NlmUniqueID>\n            <ISSNLinking>1699-048X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>207SMY3FQT</RegistryNumber>\n                <NameOfSubstance UI="D000077484">Vemurafenib</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077484" MajorTopicYN="N">Vemurafenib</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Japanese patients</Keyword>\n            <Keyword MajorTopicYN="N">Melanoma</Keyword>\n            <Keyword MajorTopicYN="N">Safety</Keyword>\n            <Keyword MajorTopicYN="N">Vemurafenib</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>01</Month>\n                <Day>02</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>06</Month>\n                <Day>17</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>7</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>8</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>7</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28674996</ArticleId>\n            <ArticleId IdType="doi">10.1007/s12094-017-1706-2</ArticleId>\n            <ArticleId IdType="pii">10.1007/s12094-017-1706-2</ArticleId>\n            <ArticleId IdType="pmc">PMC5797186</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Clin Cancer Res. 2014 Oct 1;20(19):4994-5000</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25096067</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2012 Feb 23;366(8):707-14</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22356324</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2014 Apr;15(4):436-44</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24582505</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Clin Oncol. 2008 Feb;13(1):33-41</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18307017</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Postgrad Med. 2014 Apr-Jun;60(2):187-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24823520</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2013 Apr 20;31(12 ):e215-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23509307</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2010 Aug 19;363(8):711-23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20525992</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Dermatol Sci. 2015 Oct;80(1):33-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26282084</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Clin Oncol. 2001 Jun;6(3):109-16</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11706778</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2015 Jan 22;372(4):320-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25399552</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Melanoma Res. 2015 Feb;25(1):9-14</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25051202</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2015 Jun 25;372(26):2521-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25891173</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2011 Jun 30;364(26):2507-16</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21639808</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2014 Mar;15(3):323-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24508103</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Crit Rev Oncol Hematol. 2010 Apr;74(1):27-39</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19781957</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Eur Acad Dermatol Venereol. 2016 Oct;30(10 ):e84-e86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26372833</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2014 Nov 13;371(20):1867-76</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25265494</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Jpn J Clin Oncol. 2015 Apr;45(4):390-401</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25637502</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2012 Nov;367 (18):1694-703</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23020132</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'